Pseudo-AKI associated with targeted anti-cancer agents-the truth is in the eye of the filtration marker.

Autor: Vanhoutte T; Department of Nephrology, University Hospitals Leuven, Leuven, Belgium., Sprangers B; Ziekenhuis Oost-Limburg, Genk, Belgium.; Biomedical Research Institute, Department of Immunology and Infection, UHasselt, Diepenbeek, Belgium.
Jazyk: angličtina
Zdroj: Clinical kidney journal [Clin Kidney J] 2023 Jan 16; Vol. 16 (4), pp. 603-610. Date of Electronic Publication: 2023 Jan 16 (Print Publication: 2023).
DOI: 10.1093/ckj/sfad011
Abstrakt: Besides true acute kidney injury (AKI), the occurrence of pseudo-AKI has been associated with several targeted agents. To improve the management of cancer patients treated with targeted agents, we need to be aware of this and use diagnostic approaches to differentiate between pseudo-AKI and AKI. In an article by Wijtvliet et al. in this issue of CKJ , tepotinib is added to the list of targeted agents associated with pseudo-AKI. In this editorial we discuss the current literature regarding pseudo-AKI and true AKI associated with targeted agents, and subsequently propose a management strategy to monitor kidney function in patients treated with targeted agents.
Competing Interests: B.S. is member of the CKJ Editorial Board.
(© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje